CareDx, Inc (NASDAQ:CDNA) Insider Sells $702,327.06 in Stock

CareDx, Inc (NASDAQ:CDNA) insider Alexander L. Johnson sold 21,557 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now directly owns 284,983 shares in the company, valued at $9,284,746.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

CareDx Stock Performance

NASDAQ CDNA traded down $2.40 on Thursday, reaching $30.96. The company’s stock had a trading volume of 934,019 shares, compared to its average volume of 921,956. CareDx, Inc has a twelve month low of $4.80 and a twelve month high of $34.84. The stock has a market cap of $1.61 billion, a PE ratio of -9.08 and a beta of 1.78. The firm’s 50 day moving average is $19.64 and its two-hundred day moving average is $13.93.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.37. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. The company had revenue of $92.27 million during the quarter, compared to analyst estimates of $67.20 million. Equities research analysts anticipate that CareDx, Inc will post -1.49 EPS for the current fiscal year.

Hedge Funds Weigh In On CareDx

A number of large investors have recently made changes to their positions in the business. GAMMA Investing LLC increased its holdings in CareDx by 1,021.8% in the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock worth $34,000 after buying an additional 2,013 shares during the last quarter. Headlands Technologies LLC bought a new position in shares of CareDx in the fourth quarter valued at approximately $50,000. Plato Investment Management Ltd bought a new position in shares of CareDx in the second quarter valued at approximately $62,000. Quest Partners LLC bought a new position in shares of CareDx in the fourth quarter valued at approximately $117,000. Finally, Meeder Asset Management Inc. bought a new position in shares of CareDx in the second quarter valued at approximately $142,000.

Analyst Upgrades and Downgrades

Several analysts have weighed in on CDNA shares. Craig Hallum boosted their target price on shares of CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. BTIG Research upgraded shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 target price for the company in a research note on Monday. The Goldman Sachs Group boosted their target price on shares of CareDx from $16.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. HC Wainwright reiterated a “neutral” rating on shares of CareDx in a research note on Thursday, August 1st. Finally, Stephens upped their price target on shares of CareDx from $15.00 to $18.00 and gave the stock an “overweight” rating in a research report on Monday, May 13th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.